Skip to main content

Table 1 A: Baseline characteristics in patients with prolactinoma and controls; B: Metabolic and endocrine parameters in patients with prolactinoma at follow-up

From: Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study

A

Controls

IQR

or SD

Prolactinomas

IQR

or SD

p-value

controls vs. prolactinomas

B

IQR

or SD

p-value

baseline vs. follow-up

Prolactinomas follow-up

Median

or mean

Median

or mean

Median

or mean

Sex

18 female (3 post-, 15 premenopausal), 12 male

 

7 female (all premenopausal), 14 male

     

Age (years)

36.7

11.0

40.0

17

0.418

   

BMI (kg/m2)

22.9

21.0–26.6

27.5

22.4–33.5

0.018

27.5

21.5–35.0

0.686

BMI (kg/m2) in categories in absolute numbers (percent)

        

−18.4 (underweight)

1 (3.3%)

 

1 (4.8%)

  

0 (0%)

18.5–24.9 (normal)

20 (66.7%)

 

6 (28.6%)

  

2 (9.5%)

25–29.9 (overweight)

7 (23.3%)

 

7 (33.3%)

  

2 (9.5%)

30–34.9 (obese class I)

1 (3.3%)

 

4 (19%)

  

1 (4.8%)

35–39.9 (class II)

0 (0%)

 

3 (14.3%)

  

1 (4.8%

≥ 40 (class III)

1 (3.3%)

 

0 (0%)

  

0 (0%)

15 (71.4%) missing

WHR

0.86

0.06

0.89

0.12

0.309

   

Systolic BP (mmHg)

129

17

129

21

0.997

   

Diastolic BP (mmHG)

85

13

84

15

0.921

   

Prolactin (ng/ml)

9.3

7.5–12.4

247.7

105.0–722.6

< 0.001

11.6

7.6–30.4

< 0.001

Total cholesterol (mg/dl)

192.6

45.0

212.5

36.2

0.099

196.9

40.6

0.018

LDL (mg/dl)

94.5

80–127.5

130

107–147.5

< 0.001

106.5

94.3–148

0.018

HDL (mg/dl)

69.2

14.6

56.0

16.7

0.004

55.7

21.2

0.543

Triglycerides (mg/dl)

66.5

53.8–101.0

84.0

62.0–159.0

0.075

84.5

60–168.3

0.142

Fasting glucose (mg/dl)

89

86–93

88

86–96

0.939

87

82–91.5

0.191

HOMA-IR

1.89

1.40–3.11

2.32

1.64–3.59

0.151

   

HbA1c (mmol/mol)

33

31.0–34.0

34

32.5–35.5

0.069

   

Adiponectin (μg/ml)

8.8

6.1–13.3

9.3

7.0–11.5

0.723

   

Homocystein (μmol/l)

9.6

8.0–11.2

8.8

8.0–12.3

0.926

   

CRP (mg/l)

0.8

0.6–2.0

1.3

0.6–3.9

0.427

   

Estradiol (premenopausal women only) (pg/ml)

162.5

69.4

63.0

47.0

0.030

61.8

39.2

0.318

Total testosterone (men only) (ng/ml)

3.8

1.5

1.3

0.6

< 0.001

2.4

1.0

< 0.001

Free testosterone

(men only) (ng/dl)

16.6

4.6

5.6

2.7

< 0.001

9.6

4.2

0.006

LH (mIE/ml)

6.3

3.9–10.3

3.6

1.7–5.1

0.001

4.0

2.6–5.2

0.171

FSH (mIE/ml)

5.8

3.9–7.9

3.4

2.5–6.1

0.003

4.7

3.3–5.5

0.020

TSH (μU/ml)

2.1

0.8

1.9

0.7

0.421

2.3

1.2

0.333

fT4 (pmol/L)

15.0

13.3–16-0

13.4

12.5–14.7

0.051

14.9

12.4–15.9

0.127

fT3 (pmol/L)

4.9

0.7

4.1

0.7

< 0.001

4.7

0.6

< 0.001

% fat arms

30.5

9.9

31.7

7.7

0.619

   

% fat legs

30.4

9.4

31.3

6.9

0.716

   

% fat trunk

31.7

10.2

36.8

11.1

0.099

   

% fat android

32.1

12.4

38.5

13.7

0.089

   

% fat gynoid

33.6

9.7

35.5

7.6

0.463

   

% fat total body

30.7

8.6

33.3

8.0

0.282

   
  1. Patient characteristics and laboratory parameters at baseline in patients and controls and at follow-up in patients. Data are presented as mean and standard deviation or median and interquartile range depending on distribution of data.
  2. BMI body mass index, WHR waist-hip ratio, LDL low-density lipoprotein, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, HbA1c glycated haemoglobin, CRP C-reactive protein, LH luteinizing hormone, FSH follicle-stimulating hormone, TSH thyroid-stimulating hormone, fT4 free thyroxine, fT3 free triiodothyronine;